What are the indications for Isolazine (isosorbide dinitrate 20 mg + hydralazine 37.5 mg) in adult patients?

Isolazine Indications

Isolazine (isosorbide dinitrate 20 mg + hydralazine 37.5 mg) is indicated for heart failure with reduced ejection fraction (HFrEF), specifically as add-on therapy in self-identified African American patients with symptomatic HFrEF already on optimal guideline-directed medical therapy, or as an alternative in any patient with HFrEF who cannot tolerate ACE inhibitors or ARBs. 1, 2

Primary Indication: Heart Failure with Reduced Ejection Fraction

The 2022 AHA/ACC/HFSA guidelines clearly position this combination therapy within the HFrEF treatment algorithm 1, 2:

For Self-Identified African American Patients:

• Add Isolazine to existing guideline-directed medical therapy (ACE inhibitors/ARBs/ARNi, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) when patients remain symptomatic with NYHA class III-IV heart failure
• This represents a Class I, Level A recommendation based on the African-American Heart Failure Trial (A-HeFT), which demonstrated a 43% reduction in all-cause mortality 1, 2, 3, 4
• The mortality benefit is substantial: NNT of 21 to prevent one death over 12 months, and NNT of 7 over 36 months 1, 2

For All Patients (Regardless of Race):

• Use as an alternative vasodilator therapy when ACE inhibitors, ARBs, or ARNi cannot be used due to:
  • Intolerance (e.g., angioedema, intractable cough, hyperkalemia)
  • Contraindications (e.g., severe renal dysfunction, bilateral renal artery stenosis)
  • Allergy 5, 3

Dosing Strategy

Initial dose: 20 mg isosorbide dinitrate + 37.5 mg hydralazine three times daily 1, 2

Target dose: 40 mg isosorbide dinitrate + 75 mg hydralazine three times daily 1, 2

Uptitration: Increase to target dose over several weeks as tolerated, monitoring for hypotension and headache

Mechanism and Clinical Benefits

The combination works through complementary mechanisms 5:

• Isosorbide dinitrate: Venous vasodilator reducing preload
• Hydralazine: Arterial vasodilator reducing afterload AND prevents nitrate tolerance through antioxidant properties

This results in:

• Decreased left ventricular end-diastolic volume and pressure
• Reduced mitral regurgitation
• Improved stroke volume and ejection fraction
• Left ventricular reverse remodeling
• Enhanced nitric oxide bioavailability 5

Critical Caveats

Common Pitfalls:

1. Underutilization: Only 22.4% of eligible African American patients receive this therapy despite Class I guideline recommendation 6
2. Substitution error: Generic off-label combinations of separate isosorbide and hydralazine pills are NOT equivalent to the fixed-dose combination and show inferior survival outcomes 7
3. Premature discontinuation: Headache and gastrointestinal side effects are common initially but often improve with continued use 8

Tolerability Issues:

• Headache (very common, often improves over time)
• Nausea and diarrhea (more frequent than placebo) 8
• Hypotension (monitor blood pressure, especially in dialysis patients)
• Dizziness

Special Populations:

• Dialysis patients: Appears safe and may improve cardiovascular outcomes, though requires careful blood pressure monitoring 9, 8
• Pregnancy: Not specifically addressed in guidelines; individual risk-benefit assessment required

NOT Indicated For:

• Tuberculosis (Note: The FDA drug label evidence 10 refers to "Isolazine" as isoniazid for tuberculosis treatment, which is a completely different medication and should be disregarded for this question about the isosorbide dinitrate/hydralazine combination)
• Heart failure with preserved ejection fraction (HFpEF)
• Asymptomatic left ventricular dysfunction without heart failure symptoms